Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.
Jordan Clark
Advertisement
Articles by Jordan Clark
Advertisement
Latest Updated Articles
Retesting for FLT3 Mutation Status in AMLPublished: July 9th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5